Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
An integrated safety analysis of treatment with single-agent ibrutinib for up to 5 years for patients with treatment-naïve or relapsed/refractory CLL/SLL revealed adverse events that were primarily grade 1/2 and were manageable with prolonged treatment.
Identification of Baseline Characteristics That Predict Good Outcome of alloHCT in Young CLL Patients - A Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
The most important positive prognostic factor for 2-year nonrelapse mortality in chronic lymphocytic leukemia (CLL) patients following allogeneic hematopoietic stem-cell transplantation (alloSCT) is the donor HLA match. AlloSCT still remains a valid option for younger, high cytogenetic risk, refractory/relapsed CLL patients with an HLA-allele well-matched donor.
Preclinical Analyses Support Clinical Investigation of Combined Anti-CD19 CAR-T Cell, JCAR017 with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia
Ibrutinib enhances intrinsic JCAR017 activity and may improve outcomes in chronic lymphocytic leukemia patients treated with anti-CD19 CAR T therapy, irrespective of Bruton tyrosine kinase mutational status.
Long-Term Follow-Up of Chlorambucil plus Rituximab Combination as Frontline Therapy for Elderly and/or Unfit Patients with CLL, Including Risk Stratification
Treatment of elderly and/or unfit chronic lymphocytic leukemia (CLL) patients with chlorambucil plus rituximab is associated with low toxicity, a high overall response rate and durable progression-free survival, especially in patients with a mutated IGHV profile and not carrying del17p and del11q. In this low-risk subset of unfit patients, this combination could represent the optimal therapeutic option taking into consideration safety, efficacy, and cost.
Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center
Initial Results of a Multicenter, Phase II Study of Ibrutinib plus FCR (iFCR) as Frontline Therapy for Younger CLL Patients
Ibrutinib plus fludarabine/cyclophosphamide/rituximab (FCR) induces deep responses in previously untreated young patients with chronic lymphocytic leukemia (CLL), with 39% of evaluable patients achieving complete response with bone marrow minimal residual disease negativity (BM MRD-neg) and 89% achieving BM MRD-neg, significantly higher than the 20% rate seen historically with FCR alone.
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
In pooled data from 3 randomized studies, the benefit of ibrutinib on progression-free and overall survival is most marked in patients with CLL/SLL with del11q, which is not the case with ofatumumab, chlorambucil, or bendamustine/rituximab.
Outcomes of Ibrutinib Therapy by Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)
Progression-free survival for treatment-naive ibrutinib-treated chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) patients was similar regardless of age subgroup, whereas it was shorter for chlorambucil-treated patients aged ≥75 years compared with those aged 65 to
Updated Safety and Efficacy Data for Ibrutinib as First-Line Treatment in Older Patients with CLL or SLL
With a median time on study of 28.6 months, ibrutinib demonstrated an 88% reduction in risk of progression or death in an elderly chronic lymphocytic leukemia/small lymphocytic leukemia patient population, with treatment-limiting adverse events decreasing in frequency with longer follow-up.
Page 6 of 8
Results 51 - 60 of 76
Results 51 - 60 of 76